DrugPatentWatch Database Preview
Shire Company Profile
What is the competitive landscape for SHIRE, and when can generic versions of SHIRE drugs launch?
SHIRE has forty approved drugs.
There are forty-eight US patents protecting SHIRE drugs.
There are four hundred and ninety-four patent family members on SHIRE drugs in fifty-three countries and seventeen supplementary protection certificates in eleven countries.
Summary for Shire
| International Patents: | 494 |
| US Patents: | 48 |
| Tradenames: | 36 |
| Ingredients: | 27 |
| NDAs: | 40 |
| Patent Litigation for Shire: | See patent lawsuits for Shire |
| PTAB Cases with Shire as patent owner: | See PTAB cases with Shire as patent owner |
Drugs and US Patents for Shire
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shire Dev Llc | VYVANSE | lisdexamfetamine dimesylate | TABLET, CHEWABLE;ORAL | 208510-005 | Jan 28, 2017 | RX | Yes | No | 7,713,936 | ➤ Sign Up | ➤ Sign Up | ||||
| Shire Dev Llc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | 7,928,122 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Shire Development | VYVANSE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 021977-007 | Oct 30, 2014 | RX | Yes | No | 7,687,466 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Shire Dev Llc | VYVANSE | lisdexamfetamine dimesylate | TABLET, CHEWABLE;ORAL | 208510-006 | Jan 28, 2017 | RX | Yes | Yes | 7,713,936 | ➤ Sign Up | ➤ Sign Up | ||||
| Shire Development | VYVANSE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 021977-005 | Dec 10, 2007 | RX | Yes | No | 7,713,936 | ➤ Sign Up | ➤ Sign Up | ||||
| Shire Dev Llc | VYVANSE | lisdexamfetamine dimesylate | TABLET, CHEWABLE;ORAL | 208510-001 | Jan 28, 2017 | RX | Yes | No | 7,674,774 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Shire Development | VYVANSE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 021977-002 | Feb 23, 2007 | RX | Yes | No | 7,662,788 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Shire
Paragraph IV (Patent) Challenges for SHIRE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 1 mg, 2 mg, 3 mg and 4 mg | ➤ Subscribe | 2009-12-29 |
| ➤ Subscribe | Extended-release Capsules | 37.5 mg and50 mg | ➤ Subscribe | 2017-08-03 |
| ➤ Subscribe | Chewable Tablet | 500 mg, 750 mg and 1000 mg | ➤ Subscribe | 2008-10-27 |
| ➤ Subscribe | Capsules | 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg | ➤ Subscribe | 2011-02-23 |
| ➤ Subscribe | Delayed-release Tablets | 1.2 g | ➤ Subscribe | 2009-12-16 |
| ➤ Subscribe | Extended-release Capsules | 100 mg and 200 mg | ➤ Subscribe | 2006-02-02 |
| ➤ Subscribe | Extended-release Capsules | 12.5 mg and 25 mg | ➤ Subscribe | 2017-08-07 |
| ➤ Subscribe | Oral Powder | 750 mg and 1000 mg | ➤ Subscribe | 2015-11-25 |
| ➤ Subscribe | Injection | 10 mg/mL | ➤ Subscribe | 2015-08-25 |
International Patents for Shire Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | 427101 | ➤ Sign Up |
| Hungary | T60286 | ➤ Sign Up |
| New Zealand | 544162 | ➤ Sign Up |
| Mexico | PA05003129 | ➤ Sign Up |
| Ireland | 902923 | ➤ Sign Up |
| European Patent Office | 3195861 | ➤ Sign Up |
| Australia | 2001297565 | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for Shire Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0370453 | 51/2008 | Austria | ➤ Sign Up | PRODUCT NAME: ICATIBANT, WAHLWEISE IN FORM EINES PHYSIOLOGISCH ANNEHMBAREN SALZES, EINSCHLIESSLICH ICATIBANT-ACETAT; REGISTRATION NO/DATE: EU/1/08/461/001 20080711 |
| 0370453 | SPC/GB09/002 | United Kingdom | ➤ Sign Up | PRODUCT NAME: ICATIBANT, OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF, INCLUDING ICATIBANT ACETATE; REGISTERED: UK EU/1/08/461/001 20080711 |
| 1613296 | CR 2015 00042 | Denmark | ➤ Sign Up | PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226 |
| 1644019 | C01644019/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: LISDEXAMPHETAMIN; REGISTRATION NO/DATE: SWISSMEDIC 63023 27.03.2014 |
| 1644019 | SPC/GB13/052 | United Kingdom | ➤ Sign Up | PRODUCT NAME: LISDEXAMFETAMINE OPTIONALLY IN THE FORM OF A MESYLATE OR HYDROCHLORIDE SALT THEREOF; REGISTERED: UK PL08081/0050-2 20130201; UK PL08081/0062-4 20130201 |
| 0370453 | C300359 | Netherlands | ➤ Sign Up | PRODUCT NAME: ICATIBANT, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, BIJ VOORKEUR ICATIBANTACETAAT; REGISTRATION NO/DATE: EU/1/048/461/001 20080711 |
| 1644019 | 37/2016 | Austria | ➤ Sign Up | PRODUCT NAME: LISDEXAMFETAMIN, OPTIONAL IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON, INSBESONDERE EINES MESILAT-SALZES; NAT. REGISTRATION NO/DATE: 136851-136853 20160412; FIRST REGISTRATION: PL08081/0050-PL08081/0052 20130201 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
